Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Fabry disease is an X-linked lysosomal disease caused by variants in the gene. Although Fabry disease is X-linked, gene variants in females can exhibit a wide range of symptoms, challenging the traditional view of Fabry as an X-linked recessive disease. A family is presented here with a 36-year-old female who is symptomatic with chronic kidney disease and her oligosymptomatic 70-year-old father, both of whom have a heterozygous and hemizygous GLA pathogenic variant, respectively, c.1087C>T (p.R363C). Interestingly, the proband's Lyso-GL-3 levels were lower than her father's despite her more severe clinical presentation. The discordance between clinical severity and Lyso-GL-3 levels, particularly in the context of migalastat therapy, raises questions about the appropriate interpretation and use of this biomarker. The earlier and more severe symptom onset in the female proband suggests the potential role of genetic modifiers or other factors influencing disease expression. This report underscores the complexity of Fabry disease phenotypes and the limitations of current biomarkers in predicting disease severity, particularly in females. The observed paradox between clinical symptoms and biomarker levels suggests the need for a deeper understanding of the underlying mechanisms driving phenotypic variability in Fabry disease.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11736146PMC
http://dx.doi.org/10.1002/jmd2.12466DOI Listing

Publication Analysis

Top Keywords

fabry disease
20
disease
10
phenotypic variability
8
disease x-linked
8
lyso-gl-3 levels
8
fabry
6
variability gender
4
gender paradox
4
paradox r363c
4
r363c variant
4

Similar Publications

Perspectives on newborn screening for Fabry disease based on mothers' experiences in Japan.

J Genet Couns

October 2025

Department of Genetic Counseling, Graduate School of Medical Sciences, Fujita Health University, Toyoake, Aichi, Japan.

Newborn screening (NBS) for Fabry disease (FD) is an effective way to identify individuals with FD before the onset of symptoms, enabling early therapeutic treatment. The classic form of FD typically begins in early childhood or later, but the late-onset form often develops in adulthood. However, FD-NBS identifies positive cases regardless of the expected timing of symptom onset.

View Article and Find Full Text PDF

Rationale & Objective: Late-onset Anderson-Fabry disease appears in adulthood, usually with prevalent cardiac involvement. The N215S (p.Asn215Ser) missense mutation represents the most frequent late-onset variant in European countries.

View Article and Find Full Text PDF

Long-term efficacy of migalastat in females with Fabry disease.

J Med Genet

September 2025

Inherited Renal Disorders, Nephrology Department, Fundació Puigvert, IR Sant Pau, RICORS2040, Universitat Autònoma de Barcelona, Barcelona, Spain.

Background: Fabry disease is a progressive, X-linked lysosomal disorder caused by reduced or absent α-galactosidase A activity due to variants. Females with Fabry disease often experience diagnostic delays and an underappreciated disease burden owing to their variable disease presentation and progression.

Methods: We conducted a analysis of all females from the clinical studies FACETS (NCT00925301) and ATTRACT (NCT01218659) and their open-label extensions, assessing baseline characteristics and long-term efficacy of migalastat regarding cardiac and renal function and Fabry-associated clinical events (FACEs).

View Article and Find Full Text PDF